$1.36
0.075.43%
Last update: Nov 4, 9:30 AM
ALX Oncology Holdings Inc (ALXO) Stock Price, Quote, News & History
ALXONASDAQ
ALX Oncology announces Phase 2 ASPEN-06 trial results for evorpacept in combination with trastuzumab, Cyramza, and paclitaxel for HER2-positive gastric/GEJ...
You can purchase shares of ALX Oncology Holdings (NASDAQ:ALXO) through any online brokerage.
Other companies in ALX Oncology Holdings’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
ALX Oncology Holdings has a consensus price target of $3.93.
The stock price for ALX Oncology Holdings (NASDAQ: ALXO) is $1.31 last updated November 4, 2026 at 9:30 AM EST.
There are no upcoming dividends for ALX Oncology Holdings.
ALX Oncology Holdings does not have any upcoming earnings scheduled.
There is no upcoming split for ALX Oncology Holdings.
ALX Oncology Holdings is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept,...
